J.R. Penrod

2.4k total citations
40 papers, 591 citations indexed

About

J.R. Penrod is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, J.R. Penrod has authored 40 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 7 papers in Economics and Econometrics. Recurrent topics in J.R. Penrod's work include Lung Cancer Treatments and Mutations (19 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Diagnosis and Treatment (9 papers). J.R. Penrod is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Diagnosis and Treatment (9 papers). J.R. Penrod collaborates with scholars based in United States, United Kingdom and Canada. J.R. Penrod's co-authors include Yoshinori Takanashi, L. Joseph, Theresa W. Gyorkos, Julio C. Soto, Hélène Carabin, Guido Heydecke, J. Mark Thomason, James P. Lund, Jean‐Paul Collet and Jocelyne S. Feine and has published in prestigious journals such as PEDIATRICS, Annals of Oncology and Journal of Dental Research.

In The Last Decade

J.R. Penrod

38 papers receiving 563 citations

Peers

Countries citing papers authored by J.R. Penrod

Since Specialization

Citations

This map shows the geographic impact of J.R. Penrod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.R. Penrod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.R. Penrod more than expected).

Fields of papers citing papers by J.R. Penrod

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.R. Penrod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.R. Penrod. The network helps show where J.R. Penrod may publish in the future.

Co-authorship network of co-authors of J.R. Penrod

This figure shows the co-authorship network connecting the top 25 collaborators of J.R. Penrod. A scholar is included among the top collaborators of J.R. Penrod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.R. Penrod. J.R. Penrod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EPH236 Molecular Epidemiology of ROS1 Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Patterns of Testing and Positivity Across Europe Between 2018 and 2022 2024 ·Value in Health ·Peter C. Baas, Yuwei Yuan, (unknown), (unknown), Minouk J. Schoemaker, Alan Calleja, (unknown), J.R. Penrod, Abraham P. Lee, (unknown), (unknown)	1
2	EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis 2023 ·Journal of Thoracic Oncology ·Kenneth J. O’Byrne, Evan Popoff, Firas Badin, (unknown), Yong Yuan, (unknown), Laura J. Eccles, N. Varol, Nathalie Waser, J.R. Penrod, Greta Lozano‐Ortega	0
3	EE40 Identifying and Quantifying Elements of Value for Nivolumab and Ipilimumab in First-Line Non-Small Cell Lung Cancer 2023 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), J.R. Penrod	1
4	Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up 2022 ·Medical Decision Making ·Mohammad A. Chaudhary, (unknown), Gianluca Baio, E. V. Mackay, J.R. Penrod, (unknown), (unknown), (unknown), (unknown), Mohammad Khubeb Siddiqui, J. Vanderpuye-Orgle, Andrew Briggs	8
5	10P Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227 2022 ·Annals of Oncology ·Solange Peters, J.R. Penrod, Jianqing Li, Solomon J. Lubinga, Ruchira Das Gupta, Judith Bushong, Jasmine I. Rizzo, Suresh S. Ramalingam	2
6	MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States 2021 ·Journal of Thoracic Oncology ·(unknown), Mohammad A. Chaudhary, Yong Yuan, N. Varol, Peter Dale, E. Testa, (unknown), (unknown), Solomon J. Lubinga, J.R. Penrod	1
7	PCN39 TREATMENT EFFECT MODIFICATION OF IMMUNOTHERAPY-BASED REGIMENS IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS (RCTS) 2020 ·Value in Health ·Sarah Goring, Nathalie Waser, N. Varol, J.R. Penrod, Yong Yuan, (unknown)	1
8	PCN91 Estimating EQ-5D Utilities for Cost-Effectiveness Models Involving Immuno-Oncology Treatments 2020 ·Value in Health ·Mohammad A. Chaudhary, Xiaowu Sun, Yong Yuan, N. Varol, J.R. Penrod	1
9	PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER 2019 ·Value in Health ·(unknown), (unknown), A. Juarez-Garcia, (unknown), (unknown), J.R. Penrod, D. Ross Camidge, Yong Yuan	1
10	O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response 2019 ·Journal of Thoracic Oncology ·Julie R. Brahmer, Leora Horn, (unknown), Suresh S. Ramalingam, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, (unknown), Sachin Agrawal, A. Li, J.R. Penrod, Scott Antonia, Y. Bautista	6
11	P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC) 2018 ·Journal of Thoracic Oncology ·Lee S. Schwartzberg, Beata Korytowsky, J.R. Penrod, Yong Yuan, Ting Gu, T. Kim Le, (unknown), Giovanni Selvaggi	4
12	PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC ASSESSMENT OF TRIAL DATA 2018 ·Value in Health ·(unknown), N. Varol, Nathalie Waser, Juliette C. Thompson, J.R. Penrod, Yong Yuan, Beata Korytowsky, (unknown), Sarah Goring	1
13	PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON 2018 ·Value in Health ·Shannon Cope, Evan Popoff, (unknown), Rachel Goldgrub, Jeroen P. Jansen, J.R. Penrod, (unknown), D. Ross Camidge, Beata Korytowsky, Ting Gu, (unknown), A. Juarez-Garcia, T. Kim Le, Yong Yuan	2
14	OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC) 2018 ·Journal of Thoracic Oncology ·Yi‐Long Wu, (unknown), L. Zhang, Hai‐Yan Tu, Lin Wu, J. Feng, Shun Lü, C. Zhou, Juan Wang, Tony Mok, Fiona Taylor, (unknown), J.R. Penrod, Rachael Lawrance, Steven I. Blum, (unknown), Ying Cheng	1
15	Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057 2016 ·Annals of Oncology ·Martin Reck, Julie R. Brahmer, Bryan Bennett, Fiona Taylor, J.R. Penrod, Michael DeRosa, Homa Dastani, Richard J. Gralla	6
16	460P Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017 2015 ·Annals of Oncology ·Martin Reck, Cheryl D. Coon, Fiona Taylor, Michael DeRosa, J.R. Penrod, Homa Dastani, Lucinda Orsini, Richard J. Gralla	5
17	Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe 2013 ·Value in Health ·Amir Goren, I. Gilloteau, J.R. Penrod, Jacek Jassem	1
18	PSS28 Economic Burden of Advanced Melanoma: Findings From A Large US Health Insurance Database 2011 ·Value in Health ·Gerry Oster, (unknown), J.R. Penrod, (unknown), John Edelsberg	3
19	The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being 2005 ·Lara D. Veeken ·Peter Panopalis, Michelle Petri, S Manzi, David Isenberg, Caroline Gordon, Jean‐Luc Senécal, J.R. Penrod, L. Joseph, Y. St. Pierre, Christian A. Pineau, Paul R. Fortin, Nurhan Sutcliffe, J. R. Goulet, D. Choquette, Tamara Grodzicky, John M. Esdaile, AE Clarke	38
20	Estimation of Direct and Indirect Costs Because of Common Infections in Toddlers Attending Day Care Centers 1999 ·PEDIATRICS ·Hélène Carabin, Theresa W. Gyorkos, Julio C. Soto, J.R. Penrod, L. Joseph, Jean‐Paul Collet	88

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact